Enliven Therapeutics Files 8-K for Material Agreement

Ticker: ELVN · Form: 8-K · Filed: Jun 16, 2025 · CIK: 1672619

Enliven Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyEnliven Therapeutics, Inc. (ELVN)
Form Type8-K
Filed DateJun 16, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: material-agreement, corporate-event

TL;DR

Enliven Therapeutics (NVTA) signed a material definitive agreement on 6/13/25. Filing details to follow.

AI Summary

Enliven Therapeutics, Inc. filed an 8-K on June 16, 2025, reporting a material definitive agreement entered into on June 13, 2025. The filing also includes other events and financial statements/exhibits. Enliven Therapeutics, formerly IMARA Inc., is incorporated in Delaware and based in Boulder, Colorado.

Why It Matters

This 8-K filing indicates a significant new agreement for Enliven Therapeutics, which could impact its business operations and future financial performance.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce significant new risks or opportunities, requiring careful evaluation of the terms and potential impact.

Key Players & Entities

  • Enliven Therapeutics, Inc. (company) — Registrant
  • June 13, 2025 (date) — Date of material definitive agreement
  • June 16, 2025 (date) — Filing date of the 8-K
  • IMARA Inc. (company) — Former company name
  • Delaware (jurisdiction) — State of incorporation
  • Boulder, Colorado (location) — Principal executive offices

FAQ

What is the nature of the material definitive agreement?

The filing does not specify the details of the material definitive agreement, only that one was entered into on June 13, 2025.

When was Enliven Therapeutics, Inc. formerly known as?

Enliven Therapeutics, Inc. was formerly known as IMARA Inc.

Where are Enliven Therapeutics' principal executive offices located?

Enliven Therapeutics' principal executive offices are located at 6200 Lookout Road, Boulder, Colorado, 80301.

What is the SEC file number for Enliven Therapeutics?

The SEC file number for Enliven Therapeutics is 001-39247.

What is the SIC code for Enliven Therapeutics?

The Standard Industrial Classification (SIC) code for Enliven Therapeutics is 2834, which corresponds to Pharmaceutical Preparations.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 16, 2025 regarding Enliven Therapeutics, Inc. (ELVN).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.